Background
Methods
Search Strategy
Eligibility Criteria
Study Selection
Data Extraction and Quality Assessment
Results
Literature Search
Study Characteristics
Study | Agea
| Sample Sizeb
| Eligibility | Iron Dose, Duration of Treatment / Follow-up | Measurements |
---|---|---|---|---|---|
Hammond et al. 1960[22] | 2-3 wks | T: 26 C: 22 | Premature birth | T: 100 mg intramuscular iron-dextran; C: No iron Treatment: 1 mo; Follow-up: 12 mo | Hematologic: Hb, HCT, PCV, RBC |
Brozovic et al. 1974[23] | 5 wks | 47 | GA: 29–37 wks BW: 920–1870 g | 36.3 mg/d oral iron Treatment and follow-up: 9 mo | Hematologic: Hb, SI, TIBC |
Lundstrom et al. 1977[2] | 2 wks | T: 40 C: 50 | BW: 1050–2000 g | T: 2 mg/kg/d oral iron; C: No iron Treatment and follow-up: 6 mo | Hematologic: Hb, MCV, reticulocyte count, SI, SF, TRNSAT, TIBC |
Iwai et al. 1986[24] | 3 mo | Formula: 30 Human milk:15 | GA: 30–40 wks BW: 1000–2499 g | Formula: 8 mg/L oral iron Treatment: 3 mo; Follow-up: 6 mo | Hematologic: Hb, RBC, SF, iron, TIBC, MCV |
Hall et al. 1993[25] | 8-10 d | High iron: 20 Low iron: 23 Human milk: 13 | GA: < 35 wks BW: < 1800 g | High: 1.3 mg/kg/d oral iron; Low: 0.3 mg/kg/d oral iron; Milk: 0.3 mg/kg/d iron Treatment: 25–34 d; Follow-up: ~11-13 wks | Hematologic: Hb, MCV, TRNSAT, SF, HCT, RBC, PLFE Development: weight, length, head circumference |
Griffin et al. 1999[26] | 3 d | A: 29 B: 34 C: 15 | GA: ≥ 32 wks BW: < 1750 g | A: 0.9 mg/dL iron formula (1.17 mg/kg/d); B: 0.5 mg/dL iron formula (0.81 mg/kg/d); C: 0.9 mg/dL iron formula until term and then 0.5 mg/dL iron formula (0.86 mg/kg/d) Treatment: 6 mo; Follow-up: 12 mo | Hematologic: Hb, plasma ferritin |
Franz et al. 2000[27] | 14/61 d | T: 68 C: 65 | BW: < 1301 g | T: 2–4 mg/kg/d oral iron once enteral feeding was tolerated; C: No iron Treatment and follow-up: Until 61 days of age | Hematologic: SF, TRNAST, HCT, MCV, MCH, RBC, ID |
Friel et al. 2001[28] | Birth | High: 29 Normal: 29 | BW: < 2500 g | High: 20.7 mg/L iron formula (0.6-5.9 mg/ kg/d); Normal: 13.4 mg/L iron formula (0.6- 3.0 mg/kg/d) Treatment and follow-up: 12 mo | Hematologic: Hb, HCT, SF, TRN, TRNSAT, MCV, PLFE Development: WTZ, GDA, HTZ Oxidative stress: MDA, PLZN, PLCU, FRAG, CAT, SOD, GHSPx Adverse effects: frequency of infection |
Aggarwal et al. 2005[29] | 50-80 d | T: 37 C: 36 | GA: ≥ 37 wks BW: < 2500 g | T: 3 mg/kg/d oral iron; C: No iron Treatment and follow-up: 8 wks | Hematologic: Hb, SF, microcytic hypochromic, NCHC, NCNC Development: weight, length, head circumference |
Miller et al. 2006[30] | 7-60 d | T: 16 C: 16 | GA: 24–32 wks | T: 3–12 mg/kg/d oral iron; C: No iron Treatment and follow-up: 2–3 wks | Hematologic: RBC, SI, SF, TIBC, ZnPP/H, sTfR Adverse effects: blood and urine isoprostanes |
Arnon et al. 2007[31] | 2 or 4 wks | 2 wks: 32 4 wks: 36 | GA: < 32 wks | 5 mg/kg/d oral iron Treatment and follow-up: 4–6 wks | Hematologic: SI, SF, sTfR, reticulocyte, Hb Adverse effects: morbidity |
Steinmacher et al. 2007[32] | 14/61 d | Early: 90 Late: 74 | BW: < 1301 g | Early (14 d): 2–4 mg/kg/d oral iron; Late (61 d): 2 mg/kg/d oral iron Treatment: until BW = 1.6x birth BW; Follow up: 5.3 yrs | Neurologic examination, neurophysiological testing (Gross Motor Functioning Classification Scale, Lincoln-Oseretzky Scale, Kaufmann Assessment Battery for Children, visual impairment, and Child Behavior Check List) |
Braekke et al. 2007[33] | 5 wks | 21 | GA: < 32 wks BW: < 1500 g | 9.4 mg/kg/d oral iron Treatment and follow-up: 1 wk | Hematologic: Hb, reticulocytes, iron, SF, TRNSAT Oxidative stress: urine isoprostane, urine 2,3 dinor, plasma total hydroperoxides Plasma antioxidants: AA, TAA, DHAA, alpha tocopherol, FRAP, GGT, total glutathione |
Sankar et al. 2009[34] | 2 wks | T: 22, C: 24 | BW: < 1500 g | T: 3–4 mg/kg/d oral iron; C: No iron Treatment and follow-up: 60 d | Hematologic: SF, Hb Adverse effects: morbidity |
Berglund et al. 2010[35] | 6 wks | T1: 78 T2: 82 C: 83 | BW: 2000–2500 g | T1: 1 mg/kg/d oral iron; T2: 2 mg/kg/d oral iron; C: No iron Treatment: 6 wks to 6 mo of age; Follow-up: up to 6 mo | Hematologic: Hb, SF, MCV, PLFE, TRN, TRNSAT, sTfR, ID, IDA Development: weight, weight SD score, length, length SD score, head circumference, head circumference SD score, knee-heel length Adverse effects: morbidity |
Item | Was a method of randomization used? | Were the groups similar at baseline regarding the most important prognostic indicators? | Were the eligibility criteria specified? | Was the outcome assessor blinded? | Was the care provider blinded? | Was the patient blinded? | Were point estimates and measures of variability presented for the primary outcome measures? | Did the analysis include an intention-to-treat analysis? |
---|---|---|---|---|---|---|---|---|
Hammond et al. 1960[22] | Y | Y | NA | NA | NA | NA | Y | Y |
Brozovic et al. 1974[23] | NA | NA | Y | NA | NA | NA | Y | N |
Lundstrom et al. 1977[2] | N | NA | Y | NA | NA | NA | Y | Y |
Iwai et al. 1986[24] | NA | NA | N | NA | N | N | Y | Y |
Hall et al. 1993[25] | Y | Y | Y | NA | NA | Y | Y | Y |
Griffin et al. 1999[26] | Y | N | Y | NA | NA | Y | N | Y |
Franz et al. 2000[27] | Y | Y | Y | NA | NA | NA | Y | N |
Friel et al. 2001[28] | Y | Y | Y | NA | NA | NA | Y | Y |
Aggarwal et al. 2005[29] | Y | Y | Y | NA | NA | Y | Y | Y |
Miller et al. 2006[30] | N | N | Y | NA | NA | NA | N | Y |
Arnon et al. 2007[31] | Y | Y | Y | NA | NA | NA | Y | N |
Steinmacher et al. 2007[32] | Y | Y | Y | NA | NA | NA | Y | Y |
Braekke et al. 2007[33] | N | NA | Y | NA | NA | NA | Y | Y |
Sankar et al. 2009[34] | Y | Y | Y | Y | N | Y | Y | Y |
Berglund et al. 2010[35] | Y | Y | Y | NA | Y | Y | Y | Y |
Effect of Iron Supplementation on Hematologic Parameters
Study | Effect | No Effect | % of ID and/or IDA | Conclusion | Comments |
---|---|---|---|---|---|
Hammond et al. 1960[22] | Hb, HCT significantly higher in T group by 3 mo; erythrocyte count significantly higher in T group by 5 mo | Blood volume, circulating Hb mass | 27.3 vs 7.7 % IDA (C vs T) | Early iron suppl. accelerates recovery from early IDA | 27 % loss to follow up; other vitamins were administrated; BW and hematologic measurements slightly higher in C vs T group |
Brozovic et al 1974[23] | At 3 mo of age, most infants had low serum iron concentrations, which remained low (6–9 mo) | NA | > 50 % IDA | Iron suppl. was insufficient to prevent IDA in most infants | No control group; all infants received vitamin K; some infants received other vitamins |
Lundstrom et al. 1977[2] | SF, Hb, MCV, TRNSAT significantly higher in T group by 3 mo | Reticulocyte count | 67 vs 0 % ID (C vs T) | LBW infants who do not receive iron suppl. may develop ID by 3 mo of age; 2 mg/kg/d iron is adequate for the prevention of IDA | 23 % loss to follow up; after 3 mo of age, an increasing number of C group infants were excluded; SF was higher than normal in C group; iron suppl. given in 2 different forms |
Iwai et al. 1986[24] | Hb, SF, MCV significantly higher in the formula group by 4 mo | RBC, SI, TIBC | 86 vs 33 % ID (human milk vs formula) | Breast-fed infants have a high risk of ID | Infants in formula group had slightly higher BW than those in human milk group; iron status of LBW infants was not evaluated |
Hall et al. 1993[25] | Hospitalization: plasma ferritin lowest in low iron group Discharge: plasma ferritin significantly lower in both formula groups 8 wks after discharge; MCV, MCH significantly lower in low iron group | Hb, HCT, reticulocyte, TRN, TRNSAT | 27, 69, 76 % IDA (high, low, human milk) | Preterm infants receive more benefit from receiving preterm infant formula containing 1.3 mg/kg/d iron vs 0.3 mg/kg/d | 44 and 25 % of infants in high and low dose groups dropped out because of prematurity related diseases; 13 % of infants in the human milk group completed the study |
Griffin et al. 1999[26] | NA | Hb | 18 vs 27 % ID (A vs B) | 0.81-1.17 mg/kg/d iron seems to meet the iron nutritional needs of preterm infants | In group C, BW was slightly lower, fewer transfusions were received, and Hb was significantly lower vs A and B; no ferritin data for Group C |
Franz et al. 2000[27] | NA | All markers of iron nutrition | 14.7 vs 40.0 % ID (T vs C) | Fewer infants in group T received blood transfusion vs group C; early iron suppl. is feasible and safe in LBW infants | 34 % loss to follow up; group C tended to have > chronic lung disease and ROP |
Friel et al. 2001[28] | NA | No difference in any hematologic parameters | 6.9 vs 13.8 % ID (normal vs high) | In terms of cognitive outcome, LBW infants did not benefit from high dose iron | No control group |
Aggarwal et al. 2005[29] | Adjusted Hb higher in T group | SF | NA | Iron suppl. marginally increases Hb in LBW infants | 42 % loss to follow up |
Miller et al. 2006[30] | NA | SI, SF, TIBC, sTfR | NA | Corrected reticulocyte count higher in the T group suggesting improved erythropoiesis | Iron suppl. was adjusted by individual iron status; CGA, weight, age at enrollment > in T group |
Arnon et al. 2007[31] | Hb, reticulocytes, iron, ferritin significantly higher in the 2 wk group at 8 wks | Reticulocytes, iron, ferritin at 4 wks of age | NA | Iron suppl. to preterm infants as early as 2 weeks of age was more beneficial for iron status, than at 4 weeks of age | All infants given 25 mg/d oral vitamin E; 35 % loss to follow up |
Braekke et al. 2007[33] | Iron, TRANSAT significantly increased | Ferritin | NA | Oral iron did not change markers of oxidative stress in LBW infants | No control group; all infants received other vitamins, including vitamin E; 15 % loss to follow up; short length of iron administration |
Sankar et al. 2009[34] | NA | SF, HCT, Hb | NA | Iron suppl. at 2 weeks of age did not improve hematological parameters at 2 mo of age in preterm very LBW infants | Iron suppl. group received folic acid and vitamin B12; uncommon iron formulation used |
Berglund et al. 2010[35] | All indicators of iron status differed significantly between groups in a dose-dependent manner | NA | 2.7, 0, 9.9 % IDA (T1, T2, C) 9.5, 3.8, 35.8 % ID (T1, T2, C) | Marginally LBW infants had higher risk of ID and IDA, especially those exclusively breastfed; 2 mg/kg/d oral iron significantly improved iron status and reduced IDA risk | NA |
Effect of Iron Supplementation on the Prevalence of Iron Deficiency and Iron-Deficiency Anemia
Effect of Iron Supplementation on Growth and Neurodevelopment
Study | Anthropometric Data | Neurodevelopmental Outcome |
---|---|---|
Hall et al. 1993[25] | No differences in growth rate, length, head circumference | NA |
Friel et al. 2001[28] | No differences in WTZ, HTZ at 12 months of age | No difference in GDA; no infant had abnormal development |
Steinmacher et al. 2007[32] | NA | More infants in the late iron suppl. group had abnormal neurologic examination; no differences in cognitive development, mobility, hearing, vision, growth; late vs early iron suppl. was not an risk factor for abnormal neurologic examination, disability, or cognitive impairment |
Aggarwal et al. 2005[29] | No differences in weight, length, head circumference | NA |
Sankar et al. 2009[34] | No difference in weight | NA |
Berglund et al. 2010[35] | No differences in weight, length, head circumference | NA |
Adverse Effects of Iron Supplementation
Study | Oxidative stress | Inhibition of Other Nutrient Absorption | Neonatal Morbidity | Blood Transfusion | Other Adverse Effects |
---|---|---|---|---|---|
Hall et al. 1993[25] | NA | NA | NA | NA | No adverse effects in infants who received higher iron intake |
Franz et al. 2000[27] | NA | NA | NA | NA | No adverse effects once enteral feeding (100 mL/ kg/d) tolerated |
Friel et al. 2001[28] | No differences in MDA, SOD, CAT between the high and normal groups; GHSPx slightly higher in the high group | PLCU and PLZN significantly lower in high group | Prevalence of respiratory infection greater in the high group | NA | NA |
Miller et al. 2006[30] | No differences in blood or urine isoprostanes | NA | NA | No difference | NA |
Arnon et al. 2007[31] | NA | NA | No difference | More transfusions in the 4 wk group vs the 2 wk group (10/ 36 vs 1/32) | NA |
Braekke et al. 2007[33] | No significant changes in urine isoprostane, 2,3-dinor, total hydroperoxides; plasma antioxidants were largely unchanged | NA | NA | NA | NA |
Aggarwal et al. 2005[29] | NA | NA | Prevalence of respiratory infection or bronchiolitis slightly higher in T vs C group (10/32 vs 3/30) | NA | 2 infants in the T group reported mild vomiting |
Sankar et al. 2009[34] | NA | NA | No difference (19 vs 22 % for T and C groups) | No difference (10 vs 13 for T and C groups) | NA |
Berglund et al. 2010[35] | NA | NA | No difference | NA | NA |